Australia: Does the act of applying for PBS listing constitute an offer to supply a pharmaceutical product?

Last Updated: 28 February 2017
Article by Lucy Hartland
Services: Intellectual Property & Technology
Industry Focus: Life Sciences & Healthcare

In pharmaceutical patent litigation, complex questions can arise about what type of conduct by a generic pharmaceutical company might amount to an infringement of a patentee's right to exploit its own invention, provided by the Patents Act 1990 (Cth) (Patents Act).

One question that has long had an unclear answer is whether an application for listing of a generic pharmaceutical on the Pharmaceutical Benefits Scheme (PBS) would amount to an 'offer to supply', in contravention of the patentee's right to exploit the originator version of the pharmaceutical. A recent decision of the Federal Court has shed new light on this issue.

In Apotex Pty Ltd v Warner-Lambert Company LLC (No 3),1 Nicholas J held that the proposed application for PBS listing would not be an 'offer to supply' within the definition of 'exploit' in the Patents Act, and would instead be no more than a mere preparatory step to enable exploitation at a later time.


In an earlier final decision2, Nicholas J held that Warner-Lambert Company LLC (together with four related entities, collectively 'Pfizer') was entitled to injunctive relief against Apotex Pty Ltd (Apotex) and Generic Partners Pty Ltd3 for threatened infringement of Australian Patent No. 714980 (Patent). The Patent concerned, among other things, the use of pregabalin for the treatment of pain. Pregabalin is currently marketed in Australia under the name Lyrica.

The decision

In determining the form of injunctive relief to which Pfizer was entitled, a key issue was whether Apotex's proposed application to its generic versions of Lyrica on the PBS would infringe the Patent.

Nicholas J observed that the 'method of treatment' claims of the Patent would not be exploited unless the specified method was performed during the term of the Patent. Further, section 117 of the Patents Act, concerning infringement by supply, did not apply in this scenario. This was because the application for PBS listing was not itself an infringing supply of a product that could be used to perform the method of treatment.

However, the question of whether Apotex's proposed PBS listing of its generic versions of Lyrica involved an exploitation of the Patent (and therefore an infringement) needed to be considered in the context of the other claims at issue. Pfizer argued that by applying for PBS listing of its generic pregabalin products, Apotex was exploiting the claimed invention by 'offering to sell or otherwise dispose of' products that resulted from the use of a method of manufacture encompassed by these claims. Nicholas J disagreed, holding that the application involved no more than an intention to engage with the statutory scheme by which Apotex would be able to offer its products at subsidised prices.

Nicholas J did not accept Pfizer's submission that the act of applying for PBS listing would otherwise involve an exploitation of the Patent. His Honour held that the application would be no more than a 'mere preparatory step' for Apotex's later supply of its products, although in an appropriate case that step may justify injunctive relief. Nicholas J distinguished other decisions dealing with the question of PBS listing and patent infringement on the basis that those decisions were made in the context of applications for interlocutory relief, in which it was necessary to also consider the 'balance of convenience' analysis (which essentially involves the court weighing up the inconvenience and injury to one party of granting an injunction against the inconvenience and injury to the other party of not doing so).

On that basis, Nicholas J ordered that the injunctive relief to which Pfizer was entitled did not include preventing Apotex from taking any steps to list its generic product on the PBS. Further, although not discussing issues of timing in detail, his Honour did not order that Apotex should be prevented from applying for PBS listing where that listing would occur before the Patent expired, commenting that whether such a listing would be made under those circumstances was a matter for the Minister of Health or his delegate.


When final orders for injunctive relief are made in cases where a pharmaceutical patent holder is otherwise entitled to an order preventing an infringer from infringing the patent in suit, it may not be possible to obtain an injunction against a generic competitor applying for a PBS listing of their product before the expiry of the patent. In other words, even where a generic competitor may be restrained from selling or supplying their product before a patent's expiry, they may not be prevented from taking the important preparatory step of seeking its listing on the PBS.

The effect of this decision on future applications for interlocutory injunctions in which a patentee seeks to restrain an alleged infringer from applying to list products on the PBS remains to be seen.


1Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) [2017] FCA 94.
2 Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238
3 Generic Partners Pty Ltd adopted Apotex's submissions and is not discussed further in this note.

This article is intended to provide commentary and general information. It should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this article. Authors listed may not be admitted in all states and territories

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Lucy Hartland
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.